Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02447276 · ClinicalTrials.gov registry record · Phase 2
Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip
A Phase 2 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 421
- Enrollment target
NCT02447276 is a Phase 2 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 421 participants.
The verdict
NCT02447276, a Phase 2 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 421 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the effectiveness of REGN475 compared to placebo in participants with pain due to osteoarthritis (OA) of the knee or hip and a history of inadequate joint pain relief or intolerance to current analgesic therapy.
Interventions
- DRUG Placebo
- DRUG REGN475
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 421 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02447276
The ClinicalTrials.gov registry entry for NCT02447276 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 421 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02447276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02447276 about?
NCT02447276 is a clinical study titled "Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip". The primary objective of this study is to evaluate the effectiveness of REGN475 compared to placebo in participants with pain due to osteoarthritis (OA) of the knee or hip and a history of inadequate joint pain relief or intolerance to current analgesic therapy.
What is the current status of trial NCT02447276?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 421 participants. The study started on 2015-05. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02447276?
The interventions under investigation include: Placebo (DRUG), REGN475 (DRUG).
Who is sponsoring clinical trial NCT02447276?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.